Organisation paid for research Program year 2025 Source: CMS Open Payments

Suffolk Multispecialty Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,985,141

519 payments

Through program year 2025, Suffolk Multispecialty Research LLC is reported as receiving $2,985,141 in research payments, across 519 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,902 14
2024 Research $41,283 5
2023 Research $177,826 132
2022 Research $333,301 214
2021 Research $706,452 99
2020 Research $757,067 43
2019 Research $964,310 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $2,066,578 21 payments
  2. Pfizer Inc. $385,574 46 payments
  3. Moderna TX, Inc. $194,906 256 payments
  4. Novartis Pharmaceuticals Corporation $102,305 5 payments
  5. Esperion Therapeutics, Inc. $73,631 151 payments
  6. Eli Lilly and Company $67,958 3 payments
  7. Kowa Research Institute, Inc. $67,192 31 payments
  8. Gilead Sciences, Inc. $15,673 3 payments
  9. Regeneron Pharmaceuticals, Inc. $6,325 2 payments
  10. Novo Nordisk AS $5,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. FOURIER OLE (Ph 4) $1,369,248 5 payments
  2. 20160250-FOURIER OLE (Ph 4) $379,130 2 payments
  3. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $288,665 36 payments
  4. 20170625-Vesalius - CV $144,265 2 payments
  5. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $102,305 5 payments
  6. A Phase 3 Randomized Doubleblind Placebocontrolled 26Week Multicenter Study With A 78Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo $96,909 10 payments
  7. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $96,202 131 payments
  8. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $93,801 111 payments
  9. Vesalius-Cv $82,565 1 payment
  10. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $73,631 151 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record